Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.62 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373592 | 0.86 | DAO (0.64) | DAORIPK1PARP1GCKHRH4 | |
| SCHEMBL30549017 | 0.82 | DAO (0.59) | DAORIPK1GCKHRH4HRH3 | |
| SCHEMBL1647417 | 0.79 | RIPK1 (0.60) | DAORIPK1PARP1HRH4HRH3 | |
| SCHEMBL29994379 | 0.79 | RIPK1 (0.60) | DAORIPK1PARP1HRH4HRH3 | |
| SCHEMBL253780 | 0.77 | ALDH1A1 (0.54) | DAORIPK1NPC1MAPT | |
| SCHEMBL1219236 | 0.77 | EGLN1 (0.55) | DAORIPK1MAPT | |
| SCHEMBL19145407 | 0.77 | DAO (0.50) | DAORIPK1PARP1GCKAURKA | |
| SCHEMBL1574005 | 0.77 | DAO (0.65) | DAORIPK1PARP1HRH4HRH3 | |
| SCHEMBL3714541 | 0.77 | DAO (1.00) | DAORIPK1PARP1AURKA | |
| SCHEMBL11300147 | 0.76 | DYRK1A (0.38) | DAOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119403787-A | 3- (Sulfonyl or iminosulfonyl) prop-2-en-1-yl ] -2-oxo-1, 2-dihydropyridine-3-carboxamide derivatives | 福临德治疗公司 | 2025-02-07 | — | — | CN | claimed |
| CN-115835909-B | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4543859-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | Flindr Therapeutics B.V. (NL) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403787-A | 3- (Sulfonyl or iminosulfonyl) prop-2-en-1-yl ] -2-oxo-1, 2-dihydropyridine-3-carboxamide derivatives | 福临德治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2023249490-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | IMMAGENE B.V. (NL) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023081730-A1 | 4-HYDROXY-2-OXO-1,2-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE DERIVATIVES AS CANNABINOID CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | TEON THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-115835909-A | Cannabinoid receptor type 2 (CB 2) modulators and uses thereof | 泰昂治疗公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | TEON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| CN-106831824-A | Pyrrolopyridines and its application containing naphthyridones structure | 江西科技师范大学 | 2017-06-13 | — | — | CN | disclosed |
| EP-2996691-A1 | COMPOUNDS FOR INHIBITING DRUG-RESISTANT STRAINS OF HIV-1 INTEGRASE | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | DAO 1861/4885RIPK1 1144/4885PARP1 4638/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | DAO 2660/4885RIPK1 4508/4885PARP1 2619/4885 |
| US-11564928-B1 | Cannabinoid receptor type 2 (CB2) modulators and uses thereof | CNR2, CNR1, GPR18 | DAO 4207/4885RIPK1 1687/4885PARP1 3044/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | DAO 4194/4885RIPK1 4376/4885PARP1 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.